Patient Related Outcome Measures (Mar 2020)

Clinically Meaningful Difference for the Infant Gastroesophageal Questionnaire Revised version (I-GERQ-R): A Quantitative Synthesis

  • Smith AB,
  • Fawkes N,
  • Kotze H,
  • Hodgkinson V,
  • Coyle C

Journal volume & issue
Vol. Volume 11
pp. 87 – 93

Abstract

Read online

Adam B Smith,1 Neil Fawkes,2 Helen Kotze,3 Victoria Hodgkinson,4 Cathal Coyle5 1Health Outcomes, Medical Affairs & Evidence Generation, Reckitt Benckiser, Hull, UK; 2Medical Excellence, Medical Affairs & Evidence Generation, Reckitt Benckiser, Hull, UK; 3Global Medical Affairs, Medical Affairs & Evidence Generation, Reckitt Benckiser, Hull, UK; 4Clinical Operations, Medical Affairs & Evidence Generation, Reckitt Benckiser, Hull, UK; 5Global Medical Affairs, Medical Affairs & Evidence Generation, Reckitt Benckiser, Slough, UKCorrespondence: Adam B SmithReckitt Benckiser, Dansom Lane, Hull HU8 7DS, UKTel +44 1482 583528Fax +44 1482 582172Email [email protected]: Gastroesophageal reflux disease (GORD) is a common condition affecting 30% of infants aged 0– 23 months. The Infant Gastroesophageal Questionnaire Revised version (I-GERQ-R) is an observer-reported outcome measures (ObsRO) developed to evaluate the impact of GORD on young infants. However, evidence regarding the clinically important difference (CID) for the I-GERQ-R is limited. The aim of this study was to determine a CID for the I-GERQ-R.Methods: A literature review was undertaken (PsycInfo, Embase, MedLine and EconLit databases) for longitudinal studies involving the I-GERQ-R. Articles were not limited by language or publication date. A random effects model was applied to calculate an overall CID, along with I2 and Q statistics. Publication bias was also assessed.Results: The search identified 42 articles; 11 were selected for full-text review and 7 articles were identified for full data extraction. The studies included a total of 661 infants (range: 30 to 313); 424 infants had been diagnosed with GORD (64%). The age range of the infants across the studies was from birth to 7 months. The overall CID was − 6.54 (95% confidence interval: − 4.35 to − 8.74), Q = 17.96, p=0.08 and I2=22.04.Conclusion: This study derived a CID for the I-GERQ-R and indicated a threshold around 6 could signify a clinically important difference for this instrument. The lower limit of the 95% confidence interval suggested a threshold of 3 to 4 could represent a minimally important difference. These results may help inform clinical decisions in evaluating meaningful change in symptom severity in children affected by GORD.Keywords: I-GERQ-R, gastro-esophageal reflux disease, minimally important difference, clinically important difference

Keywords